Suneva Medical Selects Quinnova Pharmaceuticals To Co-Promote ReFissa®--Topical Rx Facial Skin Care Treatment New Relationship Will Expand the Dermatology Prescriber Base for ReFissa, Tretinoin Cream, USP (Emollient) 0.05%
SAN DIEGO and JAMISON, Pa., June 4, 2013 /PRNewswire/ -- Suneva Medical, Inc., a privately-held aesthetics company, today announced that it has selected Quinnova Pharmaceuticals, LLC, a premier provider of therapeutic skin and wound products in the United States, to co-promote ReFissa. ReFissa is the only FDA approved 0.05% tretinoin emollient cream indicated for the treatment of fine wrinkles, mottled hyperpigmentation, and tactile roughness of facial skin. The Suneva/Quinnova relationship will expand the awareness and prescriber base of ReFissa in the U.S. dermatology community.
"Quinnova has structured its unique delivery platforms to provide superior products that address a variety of skin conditions," said Jeffrey Day, Quinnova's President, CEO and Founder. "As one of the most effective treatments for fine facial wrinkles, ReFissa strengthens our product portfolio, adding a coveted topical aesthetic solution to our portfolio and enhancing our value among healthcare professionals."
Nicholas Teti, Chairman and CEO of Suneva Medical added: "With Quinnova, we are able to access a strong and growing pharmaceutical dermatology sales team that is highly capable of driving ReFissa's retail pharmacy prescription growth."
To learn more about ReFissa, visit www.refissa.com.
For information on Quinnova Pharmaceutical products, visit www.quinnova.com.
Media interested in speaking with a Suneva Medical representative should contact Melody Demel at 619-234-0345 or firstname.lastname@example.org.
Important Safety Information: ReFissa 0.05% is a prescription medicine that may reduce fine facial wrinkles and mottled hyperpigmentation in patients who also protect their skin from the sun and wear sunscreen daily. ReFissa does not eliminate wrinkles, repair sun-damaged skin, reverse photo-aging, or restore more youthful or younger skin. Avoid medicines that may increase your sensitivity to sunlight, ask your pharmacist. Do not use if you are pregnant, attempting pregnancy, or nursing. ReFissa, early in treatment, may cause redness, itching, burning, stinging, and peeling. Please see full Prescribing Information at www.refissa.com.
About Quinnova Pharmaceuticals, LLC.
A wholly owned subsidiary of AmDerma, LLC, Quinnova Pharmaceuticals, LLC, is a specialty pharmaceutical company founded on innovative, patent-protected dermal delivery technologies. Its delivery platforms are utilized to transport safe and effective pharmaceutical ingredients through the epidermis in unique, convenient, and cosmetically elegant formulations. Addressing a wide variety of skin conditions, it is the company's mission to provide superior treatment solutions and product value to clinicians and patients alike. For more information, please visit www.quinnova.com.
About Suneva Medical, Inc.
Suneva Medical, Inc. is a privately-held aesthetics company focused on developing, manufacturing and commercializing novel, differentiated products for the general dermatology and aesthetic markets. The company currently markets ArteFill®, ReFissa® and ReGenica®Skincare in the U.S. and Bellafill™ in Canada. For more information, visit www.sunevamedical.com.
SOURCE Suneva Medical, Inc.